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Abstract
Objective: To determine if there is an increased maternal
or neonatal morbidity in overweight and obese patients
with a false positive glucose challenge test (GCT).
Methods: Patients with a body mass index (BMI) ≥ 25.0 at
registration were included in this prospective 36-month
study. The study cohort consisted of patients with a false
positive (FP) GCT, with two comparison cohorts: those with
a (1) screen negative (SN) GCT result and (2) true positive (TP)
GCT result. Risks were reported as odd ratios with 95% confidence intervals, with a P < 0.05 considered as significant.
Results: There were 60 patients in the FP cohort, 106 in
the SN cohort, and 64 in the TP cohort. When the BMI of
the FP cohort was compared with either the SN cohort or
TP cohort, differences were non-significant (SN 32.3 vs.
FP 33.3 kg/m2, P = 0.067) and (FP 33.3 vs. TP 34.4 kg/m2,
P = 0.303). When comparing the FP cohort to the SN cohort,
patients in the FP group had significantly more gestational hypertension and pre-eclampsia. There was a trend
towards delivering large for gestational weight infants and
an infant ≥ 4000 g in the FP cohort, but this fell short of
reaching statistical significance. When comparing the
FP to TP cohorts, rates of gestational hypertension, preeclampsia, and infants ≥ 4000 g were similar; however,
neonatal morbidity was increased in the TP group.
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Conclusions: Overweight and obese patients with a
FP glucose challenge screen are more likely to have
adverse maternal outcomes. Neonatal morbidity was not
increased.
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Introduction
The risk of developing gestational diabetes mellitus (GDM)
is increased 1.3–3.8 times in obese women compared to
women of normal body mass index (BMI) [1]. GDM has been
shown to increase the risk of both maternal and neonatal
morbidity [2]. Because of this correlation, the diagnosis of
GDM must be both accurate and precise. Thus, a two-step
process has been implemented to confirm the presence of
GDM: a screening test [glucose challenge test (GCT)] and a
glucose tolerance test (GTT). Previous studies demonstrated
conflicting data as to whether there is still an increased risk
of adverse maternal and neonatal outcomes after a positive screening test, even if confirmatory testing for GDM is
negative [3, 4]. In addition, many factors can affect glucose
metabolism including advanced maternal age, BMI, or
other medical co-morbidities [2]. Because the incidence of
obesity is rising in the US, it is important to identify its role
in both GDM testing and pregnancy outcomes. We sought to
examine the potential effect of adverse maternal and neonatal outcomes associated with a false positive (FP) GCT in
overweight and obese women.

Materials and methods
This study was conducted at Richmond University Medical Center,
New York, a high-risk tertiary care center for obstetrics and neo
nates. Patients that had prenatal care in our OB/GYN clinic during
the time period from November 2012 to November 2015 were identified from our clinical database and data was prospectively collected.
Patients who had a BMI ≥ 25.0, underwent an antenatal GCT, and
subsequently delivered at our institution were included in the study.
Patients with non-singleton gestations were excluded from analysis. All patients received a 1 h 50 g GCT between 24 and 28 weeks’
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gestation. Serum glucose levels were measured 1 h after a 50 g glucose
challenge was administered orally. If the GCT result was < 140 mg/dL,
then the test was considered a Screen Negative result (SN). If a GCT
result ≥ 140 mg/dL, a confirmatory 3 h 100 g GTT test was administered. For the confirmatory GTT, a 100 g glucose load was administered orally. Serum glucose levels were measured fasting, and at 1 h,
2 h, and 3 h from the time of the 100 g glucose load administration.
We utilized the Carpenter-Coustan criteria for diagnosing GDM, and
the following cutoffs were used: fasting: 95 mg/dL, 1 h: 180 mg/dL,
2 h: 155 mg/dL, and 3 h: 140 mg/dL. Serum glucose values above these
cutoffs were considered abnormal. When two or more abnormal values were present, a diagnosis of gestational diabetes was established
and the test was considered a true positive (TP). If less than two values
were abnormal, the GCT result was considered to be a FP (Figure 1).
The study cohort consisted of patients with a FP result. Demographical data, antepartum, intrapartum, as well as neonatal outcomes were compared amongst the FP, SN, and TP cohorts.
Maternal demographic data collected included age and BMI.
Antepartum factors included were parity and primigravida status.
The intra-partum factors assessed were gestational age at delivery,
preterm delivery < 34 weeks, preterm delivery 34–36.6 weeks, presence of gestational hypertension (defined as systolic blood pressure
of 140 mm Hg or more or a diastolic pressure of 90 mm Hg or more
on two occasions at least 4 h apart), preeclampsia (blood pressure
according to definition of gestational hypertension with proteinuria:
300 mg of protein or more in a 24-h urine collection or a protein (mg/
dL)/creatinine (mg/dL) ratio of 0.3 or higher), presence of maternal
fever (temperature ≥ 100.4°F), mode of delivery, and maternal chorioamnionitis, The diagnosis of clinical chorioamnionitis was made
if maternal fever was accompanied by at least two of the following

Glucose challenge test
50 g glucose load
n=230

Positive
≥ 140 mg/day
n=124

Negative
<140 mg/day
n=106

Screen negative
(SN)
n=106

Glucose tolerance test
100 g glucose load
n=124

Zero or one
abnormal CC values
n=60

False positive (FP)
n=60

Two or more
abnormal CC values
n=64

True positive (TP)
n=64

Figure 1: Schematic for assignment of patients to either the SN, FP,
or TP cohort.
CC = Carpenter and Coustan values (fasting: 95 mg/dL, 1 h: 180 mg/dL,
2 h: 155 mg/dL and 3 h: 140 mg/dL).

signs: fetal tachycardia > 160 beats per minute, maternal leukocytosis
(maternal white blood cell count ≥ 15,000 cells/mm), uterine tenderness, or foul smelling vaginal discharge. Postpartum factors included
were maternal wound infection, hospital length of stay, and readmission. Neonatal characteristics assessed included fetal weight, sex,
and Apgar score. Neonatal morbidity assessments included hypoglycemia (glucose < 40 mg/dL), hyperbilirubinemia (low risk: total
serum bilirubin (TSB) < 40th percentile for age in hours, low intermediate risk: TSB between 40th percentile – 75th percentile, high intermediate risk: TSB between 75th percentile – 95th percentile, and high
risk: TSB > 95th percentile), large for gestational age infant (defined
as an infant whose birthweight is > 90th percentile for their given gestational age), macrosomia defined as a birth weight ≥ 4000 g regardless of gestational age, birth weight ≥ 4500 g, incidence of shoulder
dystocia, observed seizures within 48 h of life, incidence of neonatal
intensive care (NICU) admission, requirement of neonatal mechanical ventilation, fetal demise, and neonatal death. NICU admissions
were left to the discretion of the admitting pediatrician.
An adverse maternal outcome was defined as any of the following: preterm delivery, gestational hypertension, preeclampsia, chorioamnionitis, maternal fever, cesarean delivery, wound infection,
and readmission. Neonatal morbidity was defined by the occurrence
of any of the following: neonatal hypoglycemia, hyperbilirubinemia, large for gestational age infant, birth weight ≥ 4000 g, birth
weight ≥ 4500 g, shoulder dystocia, observed seizures within 48 h of
life, NICU admission, requirement of neonatal mechanical ventilation, fetal demise, and neonatal death.
For patients diagnosed with GDM, the following blood glucose
targets were used for optimizing glucose control: fasting ≤ 90 mg/dL
and 2-h postprandial ≤ 120 mg/dL. If patients did not respond to dietary modification, initiation of medication with either insulin therapy or oral glyburide was determined on an individual basis.
Statistical analysis was carried out using IBM SPSS 22.0 (IBM
Corporation, Armonk, NY, USA). Univariate analysis for continuous
variables was compared using the Student’s t-test or the Mann-Whitney U-test. Categorical data was compared using χ2-test or Fisher’s
exact tests. A P-value of < 0.05 was considered statistically significant. Risks for statistically significant variables were reported as odd
ratios with 95% confidence intervals. Power analysis for a χ2-test was
conducted in G-POWER 3.1 (Faul and Erdfelder) to determine a sufficient sample size using an α of 0.05, power of 0.80 and 2 degrees
of freedom. A small-medium effect size (w = 0.21) was estimated for
outcomes with prevalence greater that 6%, based on data by Stamilio
et al. [3]. Based on the aforementioned assumptions, the desired total
sample size necessary is 223 patients.

Results
Of the 230 patients that met the inclusion criteria, 106
(46.1%) patients had a negative GCT result and were
assigned to the SN cohort. Sixty patients (26.1%) had
a positive GCT followed by a negative GTT, and were
assigned to the FP cohort. Sixty-four patients (27.8%) had
both a positive GCT and GTT, thus were included in the
TP cohort. The maternal and neonatal demographic characteristics of the three groups are summarized in Table 1.
Significant differences were seen within the three cohorts
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0.001
0.303
0.372
0.127
0.369
0.753
0.001
0.004
< 0.001
0.067
0.043
0.115
0.119
0.624
0.685
0.199
32.9 (21–41)
34.4 (25.0–55.1)
1.6 (0–8)
38.0 (28–40)
3465.5 (1191–5131)
8.9 (8–9)
7.6 (2–59)
4.2 (3–8)
29.8 (16–42)
33.3 (25.0–52.1)
1.9 (0–10)
38.5 (34–41)
3366.1 (1871–5642)
8.9 (7–9)
3.8 (2–13)
3.7 (2–7)
26.4 (13–43)
32.3 (25.0–50.8)
1.3 (0–5)
38.6 (32–42)
3211.2 (1588–4734)
8.9 (5–9)
4.2 (2–28)
3.9 (2–12)
Maternal age at delivery (years)
BMI (kg/m2)
Parity
Gestational at delivery (weeks)
Fetal weight (g)
Apgar at 5 min
Length of neonatal hospital stay (days)
Length of maternal hospital stay (days)

Factor
Mean (Range)

Table 1: Continuous variables.

SN (n = 106)

FP (n = 60)

TP (n = 64)

P-value comparing
SN to FP

P-value comparing
FP to TP
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when the patient’s age at time of delivery was assessed.
Patients in the FP group were older in age when compared
to the SN group (SN 26.4 vs. FP 29.8 years, P ≤ 0.001), and
patients in the FP group were significantly younger than
the TP group (FP 29.8, TP 32.9 years, P = 0.001). There was a
trend towards increasing BMI between cohorts, although
it did not reach statistical significance. Patients in the FP
cohort had a higher number of births compared to the
SN group (SN 1.3 vs. FP 1.9, P = 0.043), but no significance
was seen with the TP group (P = 0.372). When neonatal
and maternal lengths of stay were compared amongst the
groups, no differences were seen between the SN and FP
group. However, the mean length of neonatal and maternal hospital stay were both longer in the TP group when
compared to those with a FP test result (neonatal length
of stay FP 3.8 vs. TP 7.6 days, P = 0.001, maternal length of
stay FP 3.7 vs. TP 4.2 days, P = 0.004). There were no differences in gestational age at the time of delivery, fetal
weight, and Apgar scores among the three cohorts.
Antepartum, intrapartum, postpartum, and neonatal
outcome variables were also compared among the three
groups. The data is summarized in Table 2. Significant differences were seen between the SN and FP group. Patients
in the FP cohort had significantly higher rates of gestational hypertension (OR 1.14, 95% CI 1.03–1.25, P ≤ 0.001)
and pre-eclampsia (OR 3.11, 95% CI 1.98–9.97, P = 0.047)
when compared to the SN group. When the FP cohort was
compared to the TP cohort, rates of maternal hypertension,
pre-eclampsia, and LGA infants and infants ≥ 4000 g were
similar. The TP cohort were more likely to have maternal
fever (OR 2.45, 95% CI 1.06–5.65, P = 0.032), cesarean delivery (OR 2.53, 95% CI 1.21–5.28, P = 0.019), neonatal mechanical ventilation (OR 4.47, 95% CI 1.39–14.38, P = 0.007), NICU
admissions (OR 3.86, 95% CI 1.73–8.64, P < 0.001), and neonatal hypoglycemia (OR 5.12, 95% CI 1.78–14.74, P < 0.001),
when compared to the FP group.
No differences were seen among the three groups
when the following were compared: primigravida status,
preterm deliveries, shoulder dystocia, male sex, neonatal seizures/tremors, neonatal hyperbilirubinemia, fetal
demise, neonatal death, maternal re-admissions, and
maternal wound infections.

Discussion
The identification of patients who are at increased risk for
adverse maternal or fetal outcomes secondary to impaired
glucose tolerance during pregnancy has been an area of
longstanding investigation. Many studies have focused
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24 (22.6)
2 (1.9)
6 (5.7)
0 (0)
5 (4.7)
2 (1.9)
18 (17.0)
39 (36.8)
2 (1.9)
57 (53.8)
11 (10.4)
3 (2.8)
22 (20.8)
72 (67.9)
24 (22.6)
5 (4.7)
4 (3.8)
5 (4.7)
3 (2.8)
0 (0)
5 (4.7)
0 (0)
0 (0)
3 (2.8)
3 (2.8)

SN (n = 106)
n (%)

Values in bold represent significant differences, p <0.05

Primigravida
Preterm delivery < 34 weeks
Preterm delivery 34–36+6 weeks
Gestational hypertension
Preeclampsia
Chorioamnionitis
Maternal fever
Cesarean delivery
Shoulder dystocia
Male sex
Neonatal mechanical ventilation
Neonatal seizures/tremors
Neonatal intensive care unit admission
Low risk for hyperbilirubinemia
Low intermediate risk hyperbilirubinemia
High intermediate risk for hyperbilirubinemia
High risk for hyperbilirubinemia
Neonatal hypoglycemia
Macrosomia ≥ 4000 g
Macrosomia ≥ 4500 g
Large for gestational age
Fetal demise
Neonatal death
Maternal re-admission
Wound infection

Variable

Table 2: Categorical variables.

11 (18.3)
0 (0)
4 (6.7)
7 (11.6)
8 (13.3)
0 (0)
11 (18.3)
18 (30.0)
3 (5.0)
30 (50.0)
4 (6.7)
0 (0)
12 (20.0)
43 (71.7)
9 (15.0)
6 (10.0)
2 (3.3)
5 (8.3)
6 (10.0)
2 (3.3)
7 (11.7)
1 (1.7)
1 (1.7)
1 (1.7)
2 (3.3)

FP (n = 60)
n (%)
11 (17.2)
3 (4.7)
6 (9.4)
8 (12.5)
7 (10.9)
1 (1.6)
23 (35.9)
34 (53.1)
0 (0)
32 (50.0)
15 (23.4)
2 (3.1)
31 (48.4)
42 (65.6)
12 (18.8)
7 (10.9)
1 (1.6)
20 (31.3)
10 (15.6)
4 (6.3)
15 (23.4)
0 (0)
1 (1.6)
3 (4.8)
2 (3.1)

TP (n = 64)
n (%)
0.513
0.406
0.394
< 0.001
0.047
0.288
0.750
0.296
0.244
0.596
0.308
0.255
0.908
0.677
0.225
0.165
0.621
0.269
0.057
0.129
0.086
0.361
0.361
0.542
0.596

P-value comparing
SN to FP

1.14 (1.03–1.25)
3.11 (1.98–9.97)

OR (95% CI)

0.900
0.131
0.506
0.916
0.707
0.516
0.032
0.019
0.110
0.930
0.007
0.256
< 0.001
0.637
0.524
0.817
0.488
< 0.001
0.333
0.363
0.079
0.488
0.736
0.328
0.666

P-value comparing
FP to TP

5.12 (1.78–14.74)

3.86 (1.73–8.64)

4.47 (1.39–14.38)

2.45 (1.06–5.65)
2.53 (1.21–5.28)

OR (95% CI)
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on the implications of a FP GCT result; however, the data
is conflicting. Grotegut et al. compared 165 women with
FP GCT diagnosed by the Carpenter-Coustan criteria to a
cohort of SN patients, and found no differences in maternal or neonatal outcomes [4]. In contrast, in a cohort
comprising of 164 patients with a FP GCT, Stamilio et al.
found a higher incidence of adverse perinatal outcomes
compared to patients with a negative GCT result [3]. Interestingly, when Stamilio et al. sub-analyzed data based on
patient BMI, they found an inverse relationship between
BMI and the adverse perinatal outcomes. As the patient’s
BMI increased, adverse perinatal outcomes attributed to
a FP GCT result diminished linearly, and became statistically non-significant above a BMI of 25 kg/m2. They postulated that maternal obesity could have masked the risk
attributed to a FP GCT.
Although previous studies have attempted to elucidate the prognostic significance of a FP glucose screening test [3–6], none have exclusively focused on a group of
overweight and obese women. The presence of maternal
obesity can be a confounding factor in studies, as obese
women are at an increased risk for adverse pregnancy
outcomes, independent of a FP GCT result [4]. Adverse
outcomes attributed to maternal obesity include preeclampsia, gestational hypertension, GDM, LGA infants,
thromboembolism, as well as cardiovascular and metabolic disorders later in life [7].
In this study, overweight and obese patients with a FP
GCT result had increased risk of adverse pregnancy complications compared to patients of similar BMI with a SN
GCT result. Compared to the SN cohort, patients in the FP
group were more likely to have gestational hypertension
and pre-eclampsia. Interestingly, the incidence of gestational hypertensive disorders in the FP cohort resembled
that of the TP cohort. Additionally the incidence of delivering a LGA infant or an infant ≥ 4000 g was similar between
those in the FP cohort and the gestational diabetics (TP
cohort). A trend towards increased shoulder dystocia was
noted in the FP cohort compared to those who were SN,
however, due to the rarity of this complication, it did not
reach statistical significance.
In spite of the increased maternal morbidity in the
FP cohort, certain neonatal morbidities, including need
for mechanical ventilation, neonatal hypoglycemia, and
NICU admission remained higher among the gestational
diabetics. Gestational diabetics were also at an increased
risk for intrapartum fever and cesarean delivery. The presence of intrapartum fever, combined with neonatal hypoglycemia and mechanical ventilation requirements were
significantly higher in the TP cohort, and could have contributed to the increased rate of NICU admissions in this
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group. Thus, patients in the FP cohort represent an intermediate risk group that may benefit from further testing
and close monitoring, especially those with an increased
BMI, as this could augment risks.
Similar to other published studies, we show that
patients with impaired glucose tolerance have an
increased risk for pregnancy complications [2, 5, 6]. The
hyperglycemia and adverse pregnancy outcome (HAPO)
study prospectively examined 25,505 women that underwent a 75 g oral glucose tolerance test (OGTT) between 24
and 32 weeks of gestation [2]. The study showed an association between increasing maternal glucose levels and
the following study outcomes: birthweight above 90th percentile, cesarean delivery, elevated cord serum C-peptide
level, preterm delivery, shoulder dystocia, neonatal intensive care unit admission, hyperbilirubinemia, and preeclampsia [2]. The levels of maternal glycemia at which
adverse outcomes occurred were well below the diagnostic threshold for GDM [2].
The presence of both maternal obesity and impaired
glucose tolerance is of increasing concern. A link between
pregnancy, adiposity, and insulin resistance was first
apparent when it was observed that levels of the proinflammatory cytokine, tumor necrosis factor alpha
(TNF-α) were increased in the adipose tissue of obese
individuals [8]. Elevated levels of TNF-α impair glucose
metabolism whereas the antagonism of TNF-α increases
insulin sensitivity [8]. In addition, weight-loss was found
to be associated with a reduction of TNF-α and reversal
of insulin resistance [9]. It has been suggested that the
increase in TNF-α and other pro-inflammatory cytokines,
such as IL-6, observed in diabetic conditions, might result
from oxidative stress and inflammatory changes caused
by hyperglycemia [10].
Placental inflammation has been observed in pregnancies complicated by obesity [11] and GDM [12]. In
normal pregnancy, a highly regulated inflammatory
response is necessary to control several processes of placentation and subsequent placental function [13]. Maternal obesity and GDM have been associated with changes
in placental nutrient transporter expression and activity
[7]. The changes in placental function may be secondary
to altered inflammatory cytokine profiles in the maternal,
placental and fetal compartments leading to the co-morbidities observed in these pregnancies [7].
With regard to the fetal compartment, Atègbo
et al. demonstrated that macrosomic neonates of GDM
mothers had lower levels of adiponectin and leptin
when compared to aged matched controls [14]. Adiponectin, a physiologically active polypeptide hormone
derived from adipose tissue, exhibits insulin-sensitizing
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and anti-inflammatory properties. Leptin functions as
an appetite suppressant [7, 14]. The pro-inflammatory
mediatory, TNF-α, as well as IL-6, may be responsible
for inhibiting the inulin sensitizing effects of both adiponectin and leptin [14]. As these hormones have roles
in glucose and weight regulation and are synergistic with
one another, these findings show why neonates born to
GDM mothers are more prone to fetal macrosomia and
other associated adverse outcomes.
These findings are especially pertinent to our study.
Patients with a TP GCT are diagnosed with GDM, and are
therefore receiving the appropriate treatment and are
monitored more closely. However, those with a FP GCT
may also be at similar risk for several of these adverse outcomes, but they are not being monitored. It is clear from
this study, as well as other studies, that women with a
FP GCT result are at increased risk for adverse outcomes.
Maternal obesity adds an additional risk factor. Therefore, large prospective studies that evaluate the effects of
surveillance protocols on pregnancy outcomes in obese
women with a FP GCT results are needed.
This is the first study to evaluate maternal and neonatal outcomes associated with a FP GCT result in women
with increased BMI. We note some limitations in our study.
First, this study is underpowered to assess outcomes that
have a prevalence of < 6%. Therefore definitive conclusions cannot be inferred based on the non-significance of
these variables.
Second, when the GCT was positive, we administered
a confirmatory 100 g fasting GTT. Although this is standard in the US, diagnostic protocols differ in other parts of
the world. This limits direct comparison to other studies
that utilize the 2 h 75 mg OGTT. Differences in mean
patient age among cohorts may have also influenced outcomes. Finally, the patients that had a TP test result were
diagnosed with gestational diabetes. Therefore, it is possible that their outcomes could have been altered due to
the increased surveillance and intervention by providers.
Management and treatment of patients diagnosed with
gestational diabetes was left to the discretion of the treating obstetrician. We did not stratify patients in the TP
cohort based on what therapy they received, or whether
diet modification alone or medications were used to optimize glucose control.

Conclusion
This study reveals the potential risks of overweight and
obese women with FP GCT results may encounter during

the course of their pregnancies. Patients with FP GCT
results are more likely to experience adverse maternal
outcomes than those with a SN GCT. Large prospective
studies are needed to determine if the current guidelines
and cutoff values used for the GCT and GTT require modification for overweight and obese patients. If patients
with increased risks for maternal and fetal adverse
events can be identified, appropriate surveillance and
monitoring can be established in an attempt to optimize
outcomes.
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